Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

FALL15 N833 Adv Pedi Probs > Asthma > Flashcards

Asthma Flashcards

1
Q

The 2007 guidelines from NHLBI focus on what 4 components for asthma mgmt?

A
  • Measures to assess and monitor asthma
  • Patient education
  • Control of environmental factors and comorbid conditions affecting asthma
  • Pharmacologic therapy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Dx of asthma depends on what factors?

A
  • Episodic symptoms of airflow obstruction or airway hyperresponsiveness are present (medical hx, PE)
  • Airflow obstruction is at least partially reversible (spirometry)
  • Alternative diagnoses are excluded
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Risk factors for asthma

A
  • Family history of allergy, eczema, and asthma
  • Smoking in the home
  • Allergens including dust mites, pollen, pets
  • Premature birth
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Who is spirometry recommended for and what is its purpose?

A

Recommended for children 5 yrs. and older

Demonstrates obstruction and if it is reversible

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Additional testing that may be considered in Dxing asthma?

A
  • Chest x-ray
  • Allergy testing
  • Barium swallow (GER)
  • Sinus films (chronic sinusitis?)
  • Bronchoscopy
  • Bronchoprovocation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

DDx asthma

A
  • Allergic Rhinitis
  • Sinusitis
  • Bronchiolitis
  • Foreign body aspiration
  • Vocal cord dysfunction
  • Vascular rings
  • Laryngotracheomalacia
  • Tumor or enlarged lymph nodes
  • Tracheal stenosis
  • BPD
  • CF
  • Congenital Heart Disease
  • CHF
  • Aspiration
  • PE
  • GERD
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Relationship between asthma impairment and risk

A

Independent

some patients can still be at high risk for frequent exacerbations even if they have few day-to-day effects of asthma.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what age groups does stepwise asthma mgmt specify for?

A
  • 0-4 years
  • 5-11 years
  • 12 years and older
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What do patients with persistent asthma need, in terms of Tx?

A
  • both: long-term control medications and quick relief medications for symptoms
  • Inhaled corticosteroids are the preferred method of treatment with persistent asthma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the Asthma Control Test (ACT)?

A
  • Self rating questionnaire for the parents to assess asthma control
  • Assess daily activities, shortness of breath, SABA use and nightly symptoms
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Management of Exacerbations in the office

A
  • Inhaled beta2-agonist x3 in office
  • Systemic corticosteroids - 2 mg/kg/d not to exceed 60 mg/day
  • O2 and hospitalization if needed
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Short acting B2 agonists + anticholinergics: dosing and formulations

A

Short Acting Beta2-Agonist

  • Albuterol 90mcg/actuation MDI 2 puffs with spacer or Albuterol nebulized solution (.083%) or 2.5mg (.5cc) with 3cc NS
  • Levalbuterol (Xopenex®) 45 mcg/puff MDI 1-2 puffs or Nebulized solution: 0.025 mg/kg minimum 0.31 mg/3 ml unit dose; 0.63 mg/3 ml unit dose; 1.25 mg/3 ml unit dose

in combination with

Anticholinergics

  • Ipratropium (Atrovent®) nebulized solution 0.25mg/ml 0.25-0.5 mg
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Characteristics of mild exacerbation

A

dyspnea only w/activity (tachypnea in young kids)

PEF >70% predicted or personal best

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Characteristics of Moderate Exacerbation

A

dyspnea interferes w/or limits usual activity

PEF 40-60% predicted or personal best

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Characteristics of severe exacerbation

A

dyspnea at rest, interferes w/conversation

PEF <40 predicted or personal best

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Characteristics of life-threatening exacerbations

A

Too dyspneic to speak, perspiring, PEF <25% predicted of personal best

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Risk Factors for Death from Asthma

A
  • Past history of severe exacerbations
  • Prior ICU admission for asthma
  • Prior Intubations from asthma
  • 2+ hospitalization in the past year
  • 3+ ED visits for asthma in the past year
  • Hospitalization or ED visit in the last month
  • Increase use of inhaled SABA
  • Current or recent use of systemic corticosteroids
  • Difficulty understanding severity of disease
  • Comorbidity of cardiac or chronic respiratory disease
  • Psychosocial issues, low socioeconomics, or urban living
  • Psychiatric issues
  • Illicit drug use

Adapted from NHLBI 2007

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Exercise Induced Asthma: Dx

A

Hx of coughing, SOB, CP, or wheezing occurs during or after exercise.

Definitive Dx: spirometry or a decrease of 15% in peak flow with exertion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Exercise Induced Asthma: Tx

A

2-4 puffs SABA 5-60 minutes before exercise
or
Cromolyn or nedocromil before exercise

50% of patients respond to Leukotriene modifiers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Asthma triggers: drugs to avoid

A

Aspirin, NSAIDs, BBs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Asthma triggers: food and food additives

A

Avoid food products with sulfites if asthma symptoms associates with eating processed foods or drinking beer or wine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Nebulized Tx vs spacers for acute (non-life threatening asthma exacerbation

A

spacers equivalent to nebs + less time in ED, decrease hypoxia, lower HRs, lower cost of delivery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Metered Dose Inhalers (MDI): how to use

A
  • Shake the inhaler well before use; remove cap
  • Exhale away from inhaler
  • Bring the inhaler to your mouth.
  • Place it in your mouth between your teeth and close you mouth around it.
  • Start to breathe in slowly.
  • Press the top of you inhaler once and keep breathing in slowly (5 sec) until you have taken a full breath.
  • Remove the inhaler from your mouth, and hold your breath for about 5-10 seconds, then breathe out.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Spacers: benefit

A
  • Enhanced drug delivery, highly recommended with ICS for pediatrics
  • Canister holds drug in place. Can inhale at own pace – good for pedi who may not have high lung capacity
  • Inhale 30 sec or 5-10 breaths
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
When to refer to asthma specialist?
* Hx Inbubation in ICU * Multiple ED admissions * Unable to control * atypical sx * \>2 OCS in one year * combo ICS + LABA/LTRA * ICS if \<5yo * considering immunotherapy/omalizumab * needs more testing * comorbids affecting control, e.g. GER
26
How often should spirometry testing be done?
At Dx then Q1-2y once stabilized
27
What is FVC and what does it measure?
Forced Vital Capacity: total amt of air child can exhale forcibly after max inspiration Decrease could indicate restrictive or severe obstructive Dz (often nl in asthma)
28
What is FEV1?
amt of air expelled in 1st second of FVC Decreased in obstructive (st in restrictive)
29
How is reversibility shown in spirometry?
12-15% increase in FEV1 after inhalation of SABA
30
What is FEV1/FVC?
=% of lung volume can exhale in first one second Decrease indicates airway obstruction
31
What is a normal FEV1/FVC?
85% up to 19yo 80% for 20-39yo
32
What is FEF?
FEF 25%-75% measurement of FVC, excluding first 25% and last 25% of expiratory phase
33
Significance of FEF 25% to 75%?
measures small airway volume, may be decreased **before** changes in FEV1 or clinical sx are seen!
34
What are PEF values for Green, Yellow, and Red?
Green: 80-100% personal best Yellow: 50-80% personal best Red: \<50% personal best
35
When is it appropriate to try step down therapy?
well controlled asthma at least 3mo
36
O-4yo What are the components of intermittent asthma severity?
**Impairment** * **Sx: _\<_** 2d/wk * **Nighttime awakenings:** 0 * **SABA use:** **_\<_** 2d/wk * **Interference w/nl activity:** None **Risk:** * **exacerbations requiring OCS**: 0-1/year
37
0-4yo Mild persistent What are the components of severity?
**Impairment** * **Sx: \>** 2d/wk but not QD * **Nighttime awakenings:** 1-2x/mth * **SABA use: \>** 2d/wk but not QD * **Interference w/nl activity:** Minor limitation **Risk:** * **exacerbations requiring OCS**: \>2 exac in 6mo OR _\>_ 4 wheezing episode in 1yr lasting \> 1 day AND risk factors for persistent asthma
38
0-4yo What are the components of severity for Moderate Persistent asthma?
**Impairment** * **Sx:** Daily * **Nighttime awakenings:** 3-4x/mth * **SABA use:** Daily * **Interference w/nl activity:** Some limitation **Risk:** * **exacerbations requiring OCS**: \>2 exac in 6mo OR _\>_ 4 wheezing episode in 1yr lasting \> 1 day AND risk factors for persistent asthma
39
0-4yo What are you components of asthma severity for Severe Persistent Asthma?
**Impairment** * **Sx:** Throughout day * **Nighttime awakenings:** \>1x/week * **SABA use:** Several times/day * **Interference w/nl activity:** Extreme limitation **Risk:** * **exacerbations requiring OCS**: \>2 exac in 6mo OR _\>_ 4 wheezing episode in 1yr lasting \> 1 day AND risk factors for persistent asthma
40
What step of therapy should be taken based on asthma severity?
* **Intermittent:** Step 1 * **Mild P:** Step 2 * **Mod P:** Step 3 or 4 * **Severe P:** Step 5 or 6
41
5-11yo Components of severity for Intermittent Asthma?
**Impairment** * **Sx: _\<_** 2d/wk * **Nighttime awakenings: _\<_** 2x/mth * **SABA use:** **_\<_** 2d/wk * **Interference w/nl activity:** None * **Lung Fx:** Normal FEV1 btwn exac; FEV1 \>80% predicted; FEV1/FVC \>85% **Risk:** * **exacerbations requiring OCS**: 0-1/year
42
5-11yo Components of Severity for Mild Persistent Asthma?
**Impairment** * **Sx: \>** 2d/wk but not QD * **Nighttime awakenings:** 3-4x/mth * **SABA use:** \> 2d/wk but not QD * **Interference w/nl activity:** Minor Limitation * **Lung Fx:** FEV1 \>80% predicted; FEV1/FVC \>80% **Risk:** * **exacerbations requiring OCS**: _\>_ 2 in 1 yr
43
5-11yo Components of asthma severity for Mod Persistent Asthma
**Impairment** * **Sx:** Daily * **Nighttime awakenings:** \>1x/wk but not nightly * **SABA use:** Daily * **Interference w/nl activity:** Some Limitation * **Lung Fx:** FEV1 60-80% predicted; FEV1/FVC 75-80% **Risk:** * **exacerbations requiring OCS**: _\>_ 2 in 1 yr
44
5-11yo Components of asthma severity for Severe Persistent Asthma
**Impairment** * **Sx:** throughout the day * **Nighttime awakenings:** Often 7x/wk * **SABA use:** Several x/day * **Interference w/nl activity:** Extreme Limitation * **Lung Fx:** FEV1 \<60% predicted; FEV1/FVC \<75% **Risk:** * **exacerbations requiring OCS**: _\>_ 2 in 1 yr
45
_\>_12yo Components of severity for Intermittent Asthma?
**Impairment** * **Sx: _\<_** 2d/wk * **Nighttime awakenings: _\<_**2x/mth * **SABA use: _\<_**2d/wk * **Interference w/nl activity:** None * **Lung Fx:** Normal FEV1 btwn exac; FEV1 \>80% predicted; FEV1/FVC normal **Risk:** * **exacerbations requiring OCS**: 0-1/year
46
_\>_12yo Components of Severity for Mild Persistent Asthma?
**Impairment** * **Sx: \>** 2d/wk but not QD * **Nighttime awakenings:** 3-4x/mth * **SABA use:** \> 2d/wk but not \>1x/day * **Interference w/nl activity:** Minor Limitation * **Lung Fx:** FEV1 \>80% predicted; FEV1/FVC normal **Risk:** * **exacerbations requiring OCS**: _\>_ 2 in 1 yr
47
_\>_12yo Components of asthma severity for Mod Persistent Asthma
**Impairment** * **Sx:** Daily * **Nighttime awakenings:** \>1x/wk but not nightly * **SABA use:** Daily * **Interference w/nl activity:** Some Limitation * **Lung Fx:** FEV1 \>60 but \<80% predicted; FEV1/FVC reduced 5% **Risk:** * **exacerbations requiring OCS**: _\>_ 2 in 1 yr
48
_\>_12yo Components of asthma severity for Severe Persistent Asthma
**Impairment** * **Sx:** throughout the day * **Nighttime awakenings:** Often 7x/wk * **SABA use:** Several x/day * **Interference w/nl activity:** Extreme Limitation * **Lung Fx:** FEV1 \<60%; FEV1/FVC reduced \>5% **Risk:** * **exacerbations requiring OCS**: _\>_ 2 in 1 yr
49
Characteristics of well controlled asthma, 0-4yo
**Impairment** * **Sx: _\<_** 2d/wk * **Nighttime awakenings:** _\<_ 1x/mth * **SABA use:** **_\<_** 2d/wk * **Interference w/nl activity:** None **Risk:** * **exacerbations requiring OCS**: 0-1/year \*Consider med SEs in assessment, but intensity not correlate to control
50
0-4yo Recommended Tx action for well-controlled asthma
Maintain current tx, regular f/u q1-6 mths, consider step down if w-c at least 3mo
51
Characteristics of NOT well controlled asthma, 0-4yo
**Impairment** * **Sx: \>**2d/wk * **Nighttime awakenings:** \>1x/mth * **SABA use: \>**2d/wk * **Interference w/nl activity:** Some **Risk:** * **exacerbations requiring OCS**: 2-3/year \*Consider med SEs in assessment, but intensity not correlate to control
52
0-4yo Recommended Tx action for NOT well-controlled asthma
Step up 1 and reevaluate in 2-6wks If no clear benefit in 4-6wks, consider alternative dx or adjusting Tx For SEs consider alternative tx options
53
Characteristics of very poorly controlled asthma, 0-4yo
**Impairment** * **Sx:** througout day * **Nighttime awakenings:** \>1x/wk * **SABA use:** several x/day * **Interference w/nl activity:** Extremely **Risk:** * **exacerbations requiring OCS**: \>3/year \*Consider med SEs in assessment, but intensity not correlate to control
54
0-4yo Recommended Tx action for very poorly well-controlled asthma
Consider short course OCS Step up 1-2 steps and reevaluate in 2wks If no clear benefit in 4-6wks, consider alternative dx or adjusting Tx For SEs consider alternative tx options
55
5-11yo Characteristics of well controlled asthma
**Impairment** * **Sx: _\<_**2d/wk but _\<_1 each day * **Nighttime awakenings:** _\<_1x/mth * **SABA use:** _\<_2d/wk * **Interference w/nl activity:** None * **Lung fx:** FEV or Peak Flow \>80% PPB; FEV1/FVC \>80% **Risk:** * **exacerbations requiring OCS**: 0-1/year \*Consider med SEs in assessment, but intensity not correlate to control
56
5-11yo Recommended Tx action for well-controlled asthma
Maintain current tx, regular f/u q1-6 mths, consider step down if w-c at least 3mo
57
5-11yo Characteristics of NOT well controlled asthma
**Impairment** * **Sx: \>**2d/wk or multiple x on _\<_ 2days/wk * **Nighttime awakenings:** _\>_2x/mth * **SABA use:** \>2d/wk * **Interference w/nl activity:** Some * **Lung fx:** FEV1 or peak flow 60-80% PPB; FEV1/FVC 75-80% **Risk:** * **exacerbations requiring OCS**: _\>_2/year \*Consider med SEs in assessment, but intensity not correlate to control
58
5-11yo Recommended Tx action for NOT well-controlled asthma
Step up at least 1 and reevaluate in 2-6wks For SEs consider alternative tx options
59
5-11yo Characteristics of very poorly controlled asthma
**Impairment** * **Sx:** througout day * **Nighttime awakenings:** _\>_2x/wk * **SABA use:** several x/day * **Interference w/nl activity:** Extremely * **Lung fx:** FEV1 or Peak Flow \<60% PPB; FEV1/FVC \<75% **Risk:** * **exacerbations requiring OCS**: _\>_2/year \*Consider med SEs in assessment, but intensity not correlate to control
60
5-11yo Recommended Tx action for very poorly well-controlled asthma
Consider short course OCS Step up 1-2 steps and reevaluate in 2wks For SEs consider alternative tx options
61
_\>_12yo Characteristics of well controlled asthma
**Impairment** * **Sx: _\<_**2d/wk * **Nighttime awakenings: _\<_**2x/mth * **SABA use: _\<_** 2d/wk * **Interference w/nl activity:** None * **Lung fx:** FEV or Peak Flow \>80% PPB * **Questionnaires:** ATAQ, ACQ, ACT **Risk:** * **exacerbations requiring OCS**: 0-1/year \*Consider med SEs in assessment, but intensity not correlate to control
62
_\>_12yo Recommended Tx action for well-controlled asthma
Maintain current tx, regular f/u q1-6 mths, consider step down if w-c at least 3mo
63
_\>1_2yo Characteristics of NOT well controlled asthma
**Impairment** * **Sx: \>**2d/wk * **Nighttime awakenings:** 1-3x/wk * **SABA use:** \>2d/wk * **Interference w/nl activity:** Some * **Lung fx:** FEV1 or peak flow 60-80% PPB * **Questionnaire:** ATAQ, ACQ, ACT **Risk:** * **exacerbations requiring OCS**: _\>_2/year \*Consider med SEs in assessment, but intensity not correlate to control
64
_\>_12yo Recommended Tx action for NOT well-controlled asthma
Step up 1 and reevaluate in 2-6wks For SEs consider alternative tx options
65
_\>_12yo Characteristics of very poorly controlled asthma
**Impairment** * **Sx:** througout day * **Nighttime awakenings:** _\>_4x/wk * **SABA use:** several x/day * **Interference w/nl activity:** Extremely * **Lung fx:** FEV1 or Peak Flow \<60%PPB * **Questionnaire:** ATAQ, ACQ, ACT **Risk:** * **exacerbations requiring OCS**: _\>_2/year \*Consider med SEs in assessment, but intensity not correlate to control
66
_\>_12yo Recommended Tx action for very poorly well-controlled asthma
Consider short course OCS Step up 1-2 steps and reevaluate in 2wks For SEs consider alternative tx options
67
0-4yo Steps 1-6
* **Step 1:** SABA prn * **Step 2:** Low-dose ICS (or cromolyn, montelukast) * **Step 3:** Medium dose ICS * **Step 4:** Med dose ICS + LABA/Montelukast * **Step 5:** Hight Dose ICS + LABA/Montelukast * **Step 6:** Hight Dose ICS +LABA/Montelukast, OCS
68
5-11yo Steps 1-6
* **Step 1:** SABA prn * **Step 2:** Low-dose ICS (or cromolyn, LTRA, Nedocromil, Theophylline) * **Step 3:** Either low dose ICS + LABA/LTRA/theophy OR Medium dose ICS * **Step 4:** Med dose ICS + LABA (or med dose ICS + LTRA/Theo) * **Step 5:** Hight Dose ICS + LABA (or high dose ICS + LTRA/theo) * **Step 6:** Hight Dose ICS +LABA +OCS (or high dose ICS + LTRA/theo + OCS)
69
_\>_12yo Steps 1-6
* **Step 1:** SABA prn * **Step 2:** Low-dose ICS (or cromolyn, LTRA, Nedocromil, Theophylline) * **Step 3:** Either low dose ICS + LABA OR Med dose ICS (or low dose ICS + LTRA/Theo/Zileuton) * **Step 4:** Med dose ICS + LABA (or med dose ICS + LTRA/Theo/zileuton) * **Step 5:** High Dose ICS + LABA AND consider omalizumab if allergies * **Step 6:** High Dose ICS +LABA +OCS AND consider omalizumab if allergies

FALL15 N833 Adv Pedi Probs (10 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions